Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Immunotherapy has significantly improved the clinical outcome of patients with cancer.
However, the immune response rate varies greatly, possibly due to lack of effective …

PURPOSE The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor)
has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF …

Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic in a
subset of papillary renal cell carcinomas. Here, using comprehensive genomic profiling …

Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation, and survival. Overexpression and overactivation of …

Background Many patients with non-small cell lung cancer (NSCLC) derive poor benefit
from immunotherapy (IO). For some of them, adding chemotherapy (CT) can improve the …

Importance Lung cancer remains the leading cause of cancer-related death globally; non–
small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases, and cigarette …

Introduction The effect of platinum-based chemotherapy (Chem.) and second-or multiple-
line immune checkpoint PD-1 blocking therapy by Nivolumab or Pembrolizumab (ICI) was …

Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …